盤中異動 | 藥明生物盤中下跌5%,報於71.25港元
2022年6月29日13時34分,藥明生物(HK02269)盤中下跌5%,報於71.25港元,成交額達9.26億港元,換手率達到0.29%。
6月24日訊,國泰君安國際發表報告指,藥明生物(02269.HK)業務增速強勁,目前的估值和價格相對合理,建議逢低買入。
6月24日,申萬宏源:首予藥明生物(02269)“買入”評級,目標價102港元。6月24日,國泰君安(香港):藥明生物(02269)業務增速強勁,建議逢低買入。6月17日,大和:維持藥明生物(02269)“買入”評級,目標價72港元。
最新的財務數據顯示,公司於2021年4季度,營業收入102.9億人民幣,淨利潤35.09億人民幣;營業收入同比增加83.35%,毛利潤同比增加90.05%,淨利潤同比增加107.28%。
盈立趨勢長盈模型最近一次交易信號,2022年6月2日出現關注信號,觸發價格爲57.0港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.